Cailin Conner

DocwireNews

Federal emergency authorities invoked during the COVID-19 pandemic expanded the use of telehealth for new and continued care. This expansion included the provision of <a href="https://www.cdc.gov/opioids/framework/surveillance-research/moud-study.html">medications for opioid use disorder</a> (MOUD). MOUD is an evidence-based approach for treating individuals with opioid use disorder (OUD), typically using three medications which include methadone, buprenorphine, and extended-release naltrexone. Researchers examined how the facilitated provision of MOUD for OUD treatment affected Medicare beneficiaries before and during the pandemic.The longitudinal study, published in <a href="https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2795953">JAMA Psychiatry</a>, examined data from the U.S. Centers for Medicare &amp; Medicaid Services from September 2018 to February 2021. Medicare fee-for-service beneficiaries 18 years and older with an <a href="https://www.cdc.gov/nchs/icd/icd-10-cm.htm">International Statistical Classification of Diseases, Tenth Revision, Clinical Modification</a> OUD diagnosis were divided into two cohorts for analysis. The pre-pandemic cohort was observed from September 2018 to February 2020 and the COVID-19 pandemic cohort was observed during the pandemic (September 2019 to February 2021). The main outcomes measured included receipt and retention of MOUD, receipt of OUD and behavioral health-related telehealth services, and incidence of medically treated overdose.The pre-pandemic cohort consisted of 105,240 beneficiaries, of which 58.1% were female, 67.6% were aged 45 to 74 years, and 79.5% were non-Hispanic White. The pandemic cohort was made up of 70,538 beneficiaries. Of the pandemic cohort, 57.1% were female, 66.3% were aged 45 to 74 years, and 79.7% were non-Hispanic White. When compared to the pre-pandemic cohort, a larger percentage of beneficiaries in the pandemic cohort received OUD-related telehealth services (19.6% versus 0.6%), behavioral health-related telehealth services (41% versus 1.9%), and MOUD (12.6% versus 10.8%). During the study period, beneficiaries in both cohorts experienced medically treated overdoses at a comparable rate; the rate in the pre-pandemic cohort was 18.5% compared to 18.4% in the pandemic cohort.Additionally, receipt of OUD-related telehealth services in the pandemic cohort was associated with lower odds of medically treated overdose (adjusted odds ratio [aOR], 0.67) and increased odds of MOUD retention (aOR, 1.27). Beneficiaries receiving MOUD from opioid treatment programs only (aOR 0.54) and those in the pandemic cohort receiving buprenorphine from pharmacies only (aOR 0.91) had lower odds of medically treated overdose when compared with beneficiaries who did not receive MOUD.The authors concluded that the expanded use of telehealth and MOUD provisioning improved retention in care and reduced odds of medically treated overdose. They suggest that &ldquo;strategies to expand provision of MOUD and increase retention in care are urgently needed.&rdquo;

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Expanded Use of Telehealth Helped Opioid Use Disorder During COVID Pandemic

COVID-19

Federal emergency authorities invoked during the COVID-19 pandemic expanded the use of telehealth for new and continued care. This expansion included the provision of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe